MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET

GlobeNewsWire • Feb 19, 2026

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Feb 18, 2026

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Feb 9, 2026

2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion

MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD's 2026 business outlook highlights expanding commercial assets, key regulatory milestones, and a strong pipeline, positioning 2026 as a potential breakout year. Afrezza's FDA label update removes adoption barriers, expanding its addressable market and supporting MNKD's long-term growth thesis.

Seeking Alpha • Feb 6, 2026

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin

GlobeNewsWire • Jan 26, 2026

MoneyShow's Best Investment Ideas For 2026: Part 5

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 5 of this series includes Hormel Foods, IonQ, Kodiak AI, Lara Exploration and MannKind.

Seeking Alpha • Jan 15, 2026

MannKind (MNKD) Upgraded to Strong Buy: Here's What You Should Know

MannKind (MNKD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Jan 13, 2026

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Top stock-market newsletter editors share gems from their ‘buy' list.

Market Watch • Jan 12, 2026

MannKind Provides Business Updates and 2026 Growth Drivers

DANBURY, Conn. and WESTLAKE VILLAGE, Calif.

GlobeNewsWire • Jan 8, 2026

Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?

On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (MNKD +0.00%), executed an exercise and immediate sale of 65,804 common shares for a transaction value of approximately $395,482, according to the SEC Form 4 filing.

The Motley Fool • Dec 24, 2025